Brand Name
Blujepa
Generic Name
Gepotidacin
View Brand Information FDA approval date: March 25, 2025
Classification: Triazaacenaphthylene Bacterial Type II Topoisomerase Inhibitor
Form: Tablet
What is Blujepa (Gepotidacin)?
BLUJEPA is a triazaacenaphthylene bacterial type II topoisomerase inhibitor indicated for the treatment of the following infections caused by susceptible microorganisms: Uncomplicated urinary tract infections in female adult and pediatric patients 12 years of age and older weighing at least 40 kilograms .
Approved To Treat
Top Global Experts
Save this treatment for later
Not sure about your diagnosis?
Related Clinical Trials
There is no clinical trials being done for this treatment